MediFind
Condition

Epidermolysis Bullosa

Symptoms, Doctors, Treatments, Research & More

Active Clinical Trials

Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 6
  • Start Date: October 15, 2020
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 10
  • Start Date: September 2020
A Safety Study of the Administration of MSC Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds
Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 24
  • Start Date: June 9, 2020
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Clinical Trial
Other
  • Status: Recruiting
  • Study Type: Other
  • Participants: 100
  • Start Date: March 2, 2020
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Clinical Trial
Other
  • Status: Not yet recruiting
  • Participants: 66
  • Start Date: March 2020
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
Clinical Trial
Biological
  • Status: Recruiting
  • Study Type: Biological
  • Participants: 15
  • Start Date: January 10, 2020
VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Clinical Trial
Biological
  • Status: Enrolling by invitation
  • Study Type: Biological
  • Participants: 3
  • Start Date: January 10, 2020
Phase I/II ex Vivo Gene Therapy Clinical Trial for RDEB Using Autologous Skin Equivalent Grafts Genetically Corrected With a COL7A1-encoding SIN Retroviral Vector
Clinical Trial
Other
  • Status: Active, not recruiting
  • Study Type: Other
  • Participants: 1
  • Start Date: December 10, 2019
SASS 3: Self-Assembled Skin Substitute (SASS) for the Treatment of Epidermolysis Bullosa